Immutep (ASX:IMM) completed the enrolment target of 40 patients for the EFTISARC-NEO second phase trial in Warsaw, Poland, according to a Wednesday filing with the Australian bourse.

The EFTISARC-NEO trial is evaluating the immunotherapy eftilagimod alpha in combination with radiotherapy Keytruda in the neoadjuvant setting for patients with resectable soft tissue sarcoma, the filing said.

It earlier reported that the combination achieved a greater than three-fold increase in tumor hyalinization/fibrosis at the time of surgical resection among 21 patients available for primary endpoint assessment.

Data updates from the trial are expected in 2025, per the filing.